Praxis down on trial setback for seizure therapy
Source: SeekingAlpha
2026-06-02 07:37:18 ET
More on Praxis Precision Medicines
- Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
- Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
- Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential
- Praxis Precision Medicines GAAP EPS of -$3.20
- Praxis Precision gains as lead asset accepted for FDA review
Read the full article on Seeking Alpha
For further details see:
Praxis down on trial setback for seizure therapy
Praxis Precision Medicines Inc.
NASDAQ: PRAX
PRAX Trading
-3.47% G/L:
$261.18 Last:
202,126 Volume:
$264.18 Open:
PRAX Latest News
June 04, 2026 04:01:00 pm
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
PRAX Stock Data
$8,057,264,446
20,105,683
0.7%
83
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
